Mirum Pharmaceuticals, Inc.
MIRMHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeMirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company carries a $6.19B market cap, placing it firmly in the mid-cap category. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Market Cap
$6.19B
Beta
0.52
P/E (TTM)
—
P/E (Fwd)
-181.90
EPS (TTM)
$-13.60
EPS (Fwd)
$-0.56
ROE
-335.8%
ROA
-5.9%
Cash
$386.3M
Total Debt
$323.8M
Free CF
$166.9M
52W Change
120.8%
Annual Financials
Cash vs Debt
Mirum Pharmaceuticals, Inc. holds $386.3M in cash against $323.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $166.9M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of -335.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $77.1M (2022) to $521.3M (2025), reflecting a 576% increase over the period.
The relatively low beta of 0.52 suggests MIRM is a less volatile holding compared to the broader index. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Mirum Pharmaceuticals, Inc. and its sector.